Literature DB >> 8837586

C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems.

R S Wright1, C M Wei, C H Kim, M Kinoshita, Y Matsuda, L L Aarhus, J C Burnett, W L Miller.   

Abstract

OBJECTIVES: We tested the hypothesis that C-type natriuretic peptide (CNP) mediates coronary vasodilation through activation of cyclic guanosine monophosphate (cGMP) by way of particulate guanylate cyclase.
BACKGROUND: CNP has known peripheral vasodilator properties, and preliminary data have suggested that it can function as a coronary vasodilator.
METHODS: The actions of CNP were studied in instrumented dogs and in organ chamber rings in the presence and absence of a known antagonist to particulate guanylate cyclase, HS-142-1. Additionally, the actions of HS-142-1 were tested on acetylcholine-mediated coronary vasodilation, and immunohistochemical staining was utilized to localize the presence of CNP in the coronary endothelium.
RESULTS: CNP relaxed isolated coronary arteries with (mean +/- SEM 45.9 +/- 7%*) and without (72.0 +/- 7%*) an endothelium (*p < 0.05 for CNP effect alone, p < 0.05 for endothelium vs. no endothelium with CNP). Intracoronary infusions increased coronary blood flow (baseline, 64.6 +/- 5.1 ml/min; CNP-5, 79.9 +/- 6.1*; CNP-20, 103.3 +/- 13.6* [*p < 0.05 vs. baseline value]) and reduced coronary vascular resistance (baseline, 1.6 +/- 0.3 mm Hg/ml per min; CNP-5, 1.4 +/- 0.3*; CNP-20, 1.2 +/- 0.3*). Intracoronary injections increased coronary blood flow (delta baseline coronary flow, 30 +/- 9* ml/min [*p < 0.05]). HS-142-1 significantly attenuated these increases (delta coronary flow, 30 +/- 9* ml/min [CNP] to 14 +/- 6 [CNP + HS-142-1] [p < 0.05 CNP vs. CNP + HS-142-1]) and the relaxation of organ chamber rings (56 +/- 7% [CNP] to 18 +/- 6% [HS-142-1 + CNP]). Finally, CNP was localized to the coronary endothelium and smooth muscle by immunohistochemical staining.
CONCLUSIONS: CNP functions as a coronary vasodilator through activation of cGMP by way of particulate guanylate cyclase. CNP-mediated coronary vasodilation is attenuated by intracoronary HS-142-1. Intracoronary HS-142-1 does not affect acetylcholine-mediated coronary vasodilation. These observations support a role for exogenous CNP as a potent coronary vasodilator.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8837586     DOI: 10.1016/s0735-1097(96)00241-0

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

Review 1.  Coronary endothelial function in health and disease.

Authors:  J C Burnett
Journal:  Drugs       Date:  1997       Impact factor: 9.546

2.  Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population.

Authors:  S Jeson Sangaralingham; Paul M McKie; Tomoko Ichiki; Christopher G Scott; Denise M Heublein; Horng H Chen; Kent R Bailey; Margaret M Redfield; Richard J Rodeheffer; John C Burnett
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

Review 3.  CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.

Authors:  Paul M McKie; S Jeson Sangaralingham; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2010-09

4.  Serum levels of natriuretic peptides in patients with Behcet's disease.

Authors:  Ramazan Yağci; Yüksel Totan; Ekin Ozlük; Hüseyin Ozyurt; Gülfer Akbay; Meral Ekşioğlu
Journal:  Clin Rheumatol       Date:  2008-04-15       Impact factor: 2.980

5.  C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Authors:  Tiankai Li; Heng-Jie Cheng; Nobuyuki Ohte; Hiroshi Hasegawa; Atsushi Morimoto; David M Herrington; William C Little; Weimin Li; Che Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2016-03-29       Impact factor: 4.030

6.  Comparative study in the effect of C-type natriuretic peptide on gastric motility in various animals.

Authors:  Hui-Shu Guo; Zheng Jin; Zheng-Yuan Jin; Zhe-Hao Li; Yi-Feng Cui; Zuo-Yu Wang; Wen-Xie Xu
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

7.  Atrial natriuretic peptide affects cardiac remodeling, function, heart failure, and survival in a mouse model of dilated cardiomyopathy.

Authors:  Dong Wang; Inna P Gladysheva; Tai-Hwang M Fan; Ryan Sullivan; Aiilyan K Houng; Guy L Reed
Journal:  Hypertension       Date:  2013-12-30       Impact factor: 10.190

8.  Vascular relaxation induced by C-type natriuretic peptide involves the ca2+/NO-synthase/NO pathway.

Authors:  Fernanda A Andrade; Carolina B A Restini; Marcella D Grando; Leandra N Z Ramalho; Lusiane M Bendhack
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

Review 9.  C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Authors:  Amie J Moyes; Adrian J Hobbs
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

Review 10.  Atrial Natriuretic Peptide31-67: A Novel Therapeutic Factor for Cardiovascular Diseases.

Authors:  Gustavo Jose Justo da Silva; Raffaele Altara; George W Booz; Alessandro Cataliotti
Journal:  Front Physiol       Date:  2021-07-08       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.